- Home
- CFG vs MRNA Comparison
CFG vs MRNA Comparison
Compare CFG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFG
- MRNA
- Stock Information
- Founded
- CFG 1828
- MRNA 2010
- Country
- CFG United States
- MRNA United States
- Employees
- CFG N/A
- MRNA N/A
- Industry
- CFG Major Banks
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CFG Finance
- MRNA Health Care
- Exchange
- CFG Nasdaq
- MRNA Nasdaq
- Market Cap
- CFG 19.2B
- MRNA 16.0B
- IPO Year
- CFG 2014
- MRNA 2018
- Fundamental
- Price
- CFG $47.55
- MRNA $34.06
- Analyst Decision
- CFG Buy
- MRNA Hold
- Analyst Count
- CFG 17
- MRNA 20
- Target Price
- CFG $47.35
- MRNA $76.35
- AVG Volume (30 Days)
- CFG 4.0M
- MRNA 10.7M
- Earning Date
- CFG 01-17-2025
- MRNA 02-20-2025
- Dividend Yield
- CFG 3.53%
- MRNA N/A
- EPS Growth
- CFG N/A
- MRNA N/A
- EPS
- CFG 3.03
- MRNA N/A
- Revenue
- CFG N/A
- MRNA $5,081,000,000.00
- Revenue This Year
- CFG N/A
- MRNA N/A
- Revenue Next Year
- CFG $4.76
- MRNA N/A
- P/E Ratio
- CFG $15.71
- MRNA N/A
- Revenue Growth
- CFG N/A
- MRNA N/A
- 52 Week Low
- CFG $30.24
- MRNA $31.94
- 52 Week High
- CFG $49.25
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- CFG 64.90
- MRNA 34.88
- Support Level
- CFG $45.71
- MRNA $33.34
- Resistance Level
- CFG $47.51
- MRNA $35.68
- Average True Range (ATR)
- CFG 1.18
- MRNA 2.46
- MACD
- CFG 0.44
- MRNA -0.75
- Stochastic Oscillator
- CFG 87.01
- MRNA 12.49
About CFG Citizens Financial Group Inc.
Citizens Financial Group Inc is a bank holding company headquartered in Providence, Rhode Island. Its two primary business segments are consumer banking and commercial banking. Citizens offers a mix of retail and commercial products including capital markets and wealth options. The bank has over 1,100 branches in 14 states, although it is concentrated in the Northeast. It has over $220 billion of total assets. It generates maximum revenue from Consumer Banking Segment.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.